Hemolytic disease of the newborn occurs when a pregnant person’s immune system produces antibodies that cross the placenta and destroy the baby’s red blood cells. The most familiar version involves Rh D incompatibility, but ABO mismatches and dozens of rarer blood-group antigens can also trigger it. Although anti-D immunoglobulin prophylaxis has dramatically reduced severe cases in high-income countries since the 1960s, the disease remains a significant cause of fetal and neonatal illness worldwide, particularly in regions where prophylaxis is inconsistent or unavailable.
How a Blood Type Mismatch Becomes an Attack on the Fetus
The core problem is straightforward. During pregnancy or delivery, small amounts of fetal blood can leak into the mother’s circulation. If the fetal red blood cells carry a surface protein that the mother’s cells lack, her immune system may recognize those cells as foreign and produce antibodies against them. This initial exposure, called sensitization, often causes no harm to the first baby. The danger comes in a subsequent pregnancy. The mother’s immune system, now primed, can mount a rapid antibody response. These antibodies, specifically IgG antibodies small enough to cross the placenta, latch onto the fetal red blood cells and mark them for destruction.
As fetal red blood cells are broken down faster than they can be replaced, the baby develops anemia. The breakdown products include bilirubin, which the fetal liver struggles to process. In mild cases, the baby is born slightly jaundiced and recovers with light therapy. In severe cases, the anemia can lead to heart failure, widespread fluid accumulation known as hydrops fetalis, and brain damage from bilirubin toxicity. Without treatment, the most severe forms are fatal.
ABO Incompatibility Is Common but Usually Mild
ABO blood type mismatches between mother and baby are actually the most frequent cause of hemolytic disease of the newborn. The classic scenario involves a mother with type O blood carrying a baby with type A or B blood. Because type O individuals naturally produce anti-A and anti-B antibodies, sensitization can occur even during a first pregnancy, without any prior exposure event. Despite that, ABO hemolytic disease is almost always mild and treatable with phototherapy alone.1Journal of Pediatric Hematology/Oncology. Severe ABO Hemolytic Disease of the Newborn Requiring Exchange Transfusion
The reason ABO cases tend to be gentle has to do with the antibodies involved and their targets. The A and B antigens are expressed on many cell types throughout the body, not just red blood cells, so maternal antibodies get “soaked up” by non-red-cell tissues in the placenta and fetus. The antibodies are also often a mix of IgM (which cannot cross the placenta efficiently) and IgG, reducing the effective attack on fetal red cells. Severe ABO disease requiring exchange transfusion is rare, though it does occur. One documented case involved an O-positive mother delivering a B-positive baby who developed rapid, dangerous jaundice requiring a double-volume exchange transfusion.2Journal of Pediatric Hematology/Oncology. Severe ABO Hemolytic Disease of the Newborn Requiring Exchange Transfusion
An interesting wrinkle is that ABO hemolytic disease occasionally occurs with non-O mothers. Textbooks usually describe the O-mother-to-non-O-baby scenario, but cases have been reported in which a mother with type B blood delivered a baby with type A, and the baby developed hemolytic disease.3PubMed Central. Hemolytic Disease of Newborn due to ABO Incompatibility between B Blood Group Mother and A Blood Group Neonate These are rare and tend to catch clinicians off guard because the pairing falls outside the usual screening algorithm.
Kell, Little c, and Other Antigens That Complicate the Picture
Rh D gets the most attention, but several other blood-group antigens can cause hemolytic disease that is just as severe or even harder to manage. The Kell blood group system is the most clinically important of these. Unlike Rh D antibodies, which primarily destroy circulating red blood cells through hemolysis, anti-Kell antibodies work by a different mechanism: they suppress the production of new red blood cells at the progenitor level in the bone marrow. Research showed that monoclonal anti-Kell antibodies inhibited the growth of Kell-positive red cell progenitors in a dose-dependent fashion, while anti-D antibodies had no such effect on the same cells.4PubMed. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia
This distinction matters clinically. In Rh D disease, the fetus tries to compensate for anemia by ramping up red cell production, which shows up as an elevated reticulocyte count and high bilirubin levels in amniotic fluid. In Kell disease, that compensatory response is blunted. A study comparing fetuses affected by anti-Kell versus anti-D found significantly less reticulocytosis and lower amniotic fluid bilirubin in the Kell group, even though the anemia was equally severe.5PubMed. Erythropoietic suppression in fetal anemia because of Kell alloimmunization The practical consequence is that traditional monitoring methods based on bilirubin levels can underestimate the severity of Kell disease, making it harder to catch before the baby is in serious trouble.
Other antigens in the Rh system beyond D can also cause trouble. Antibodies against “little c” (lowercase c, distinct from big C) and anti-E have caused cases severe enough to need intrauterine transfusions and exchange transfusions after birth. In one series of five cases, the most severe disease occurred in a fetus affected by simultaneous anti-E and anti-c sensitization.6PubMed. Haemolytic disease of the newborn caused by anti-c, anti-E and anti-Fya antibodies: report of five cases The Duffy blood group system (anti-Fya) has also been implicated. These rarer causes are important because there is no prophylactic injection to prevent sensitization against them, the way anti-D immunoglobulin prevents Rh D sensitization. Once a mother develops antibodies to Kell, c, E, or Duffy antigens, every subsequent pregnancy with a positive fetus is at risk.
Detecting the Problem Before Birth
The first line of defense is antibody screening during pregnancy. All pregnant individuals should have an indirect antiglobulin test, which detects circulating antibodies in the mother’s blood that could target fetal red cells. When this screening is skipped during pregnancy, performing a direct antiglobulin test on the newborn’s blood becomes especially important. Babies born to mothers who tested positive on the indirect test tend to have a more severe clinical course.7PubMed. Neonatal hemolytic disease: How should we use indirect and direct antiglobulin tests?
When antibodies are detected, the next question is whether the fetus actually carries the targeted antigen. This is where noninvasive prenatal testing using cell-free fetal DNA has been a game-changer. Fragments of fetal DNA circulate in the mother’s blood, and laboratory analysis can determine whether the fetus is Rh D positive without any invasive procedure. Studies have demonstrated this can be done with very high accuracy, approaching near-perfect predictive value.8PubMed. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma The practical benefit is twofold: if the fetus turns out to be Rh D negative, the mother does not need anti-D immunoglobulin and can avoid unnecessary surveillance. If the fetus is positive, closer monitoring can begin early.9PubMed Central. Noninvasive Prenatal Diagnosis of Fetal RHD Status Using Cell-free Fetal DNA in Maternal Plasma
For fetuses confirmed to be at risk, Doppler ultrasound of the middle cerebral artery has become the standard way to track whether anemia is developing. When a fetus is anemic, its blood becomes thinner and flows faster. By measuring the peak speed of blood flow in the middle cerebral artery, clinicians can estimate how severe the anemia is without needing to take a blood sample from the fetus. An elevated peak systolic velocity above a certain threshold detects about 96% of severely anemic fetuses.10PubMed. Prediction of fetal anemia in rhesus disease by measurement of fetal middle cerebral artery peak systolic velocity This non-invasive approach replaced the older method of analyzing amniotic fluid bilirubin levels, which required amniocentesis and could itself trigger further sensitization.
The technique is not perfect. In a review of fetuses that had elevated middle cerebral artery peak systolic velocity and then underwent fetal blood sampling, about 6% turned out to have no significant anemia or only mild anemia. The false elevations were associated with various other conditions including intracranial hemorrhage, acidosis, and fetal growth restriction.11PubMed Central. Elevated Middle Cerebral Artery Peak Systolic Velocity in Non-Anemic Fetuses: Providing a Better Understanding of Enigmatic Middle Cerebral Artery Peak Systolic Velocity Differential Diagnosis for High MCA-PSV Doppler Clinicians interpreting these readings have to weigh the full clinical picture rather than relying on a single number.
Treatment Before Birth
When Doppler monitoring indicates the fetus is becoming dangerously anemic, the primary intervention is intrauterine transfusion. A needle is guided through the mother’s abdomen, typically into the umbilical cord at the point where it inserts into the placenta, and compatible donor red blood cells are transfused directly into the fetal circulation. The procedure can raise fetal hemoglobin levels dramatically in a single session. In one series, median fetal hemoglobin went from about 4.6 g/dL before transfusion to 12.8 g/dL afterward.12PubMed Central. Intrauterine Fetal Blood Transfusion: Descriptive study of the first four years’ experience in Oman
These transfusions are lifesaving but carry real risk. A large analysis of over 250 pregnancies treated with intrauterine transfusion found an overall survival rate of about 89%. Procedure-related complications included emergency delivery, infection, and fetal death, with a per-procedure complication rate of roughly 3% and a per-procedure loss rate of about 1.6%.13PubMed. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization Factors that increased risk included puncturing an artery rather than the vein, more advanced gestational age, and performing the transfusion through the amniotic cavity rather than directly into the cord. Severely affected fetuses often need multiple transfusions, sometimes every two to three weeks, until the baby is mature enough to be safely delivered.
Postnatal Management and the Threat of Kernicterus
After birth, the immediate concern shifts to bilirubin. Maternal antibodies that crossed the placenta are still circulating in the baby’s blood and continue destroying red cells. The newborn liver, immature even under normal circumstances, cannot process bilirubin fast enough, and levels can rise rapidly. If unconjugated bilirubin reaches the brain, it can cause acute bilirubin encephalopathy, which, if not reversed, progresses to kernicterus, a form of permanent brain damage. Research into the mechanism has shown that high levels of unbound bilirubin in the brain trigger activation of immune cells and release of inflammatory molecules, leading to cell death in vulnerable brain regions.14Research and Reports in Neonatology. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives
Phototherapy is the first-line treatment. Special blue-spectrum lights convert bilirubin in the skin into water-soluble forms the baby can excrete without liver processing. Intensive phototherapy, using higher-power light devices, is considered an emergency measure for dangerously high levels and can substantially reduce the need for exchange transfusion. Exchange transfusion, in which the baby’s blood is gradually removed and replaced with compatible donor blood, is reserved for cases where phototherapy cannot keep up with the rate of bilirubin rise or where anemia is severe.15PubMed Central. Intensive phototherapy vs. exchange transfusion for the treatment of neonatal hyperbilirubinemia: a multicenter retrospective cohort study Exchange transfusion removes both the bilirubin and the offending maternal antibodies, providing immediate relief. However, it is an invasive procedure that carries its own risks, including electrolyte imbalances and infection.
Late Anemia After Intrauterine Transfusions
One underappreciated complication affects babies who received intrauterine transfusions. After birth, many of these infants develop a prolonged, sluggish anemia that can last weeks to months. The reason is counterintuitive: the transfused donor red blood cells, which lack the targeted antigen, are not being destroyed by maternal antibodies. They adequately supply oxygen. The fetus’s own bone marrow, registering a normal hemoglobin level thanks to the donor cells, dials back its own red cell production. Meanwhile, the maternal antibodies are still present, ready to destroy any of the baby’s own red cells that the marrow does produce.
A study tracking this phenomenon found that babies with D-mediated disease who had received more than two intrauterine transfusions needed a median of three postnatal red cell transfusions, compared to two in those who received fewer intrauterine transfusions. The same pattern held in Kell-mediated disease.16PubMed. Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions Earlier case-level investigation documented a baby whose bone marrow remained suppressed for roughly three months after birth, with erythropoietin levels inappropriately low for the degree of anemia, suggesting the repeated intrauterine transfusions had essentially trained the marrow to stay quiet.17American Journal of Obstetrics and Gynecology. Hyporegenerative anemia associated with intrauterine transfusion in rhesus hemolytic disease This means families should expect ongoing monitoring and possibly additional transfusions for weeks after discharge, even if the baby seemed well at birth.
Global Gaps in Prevention
Anti-D immunoglobulin, given to Rh D-negative mothers during pregnancy and after delivery, prevents the sensitization that leads to Rh disease. It is one of the great success stories of twentieth-century medicine. Before it became widely available, Rh disease was a leading cause of perinatal death. Its discovery traces back to the identification of the Rh blood group system in 1940 by Karl Landsteiner and Alexander Wiener.18PubMed Central. Karl Landsteiner (1868-1943): A Versatile Blood Scientist
But access to anti-D immunoglobulin is strikingly uneven around the world. In Latin America, roughly 60% of eligible pregnancies receive anti-D prophylaxis.19PubMed Central. Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review In Ethiopia, Rh alloimmunization remains a major cause of perinatal illness, driven largely by the unaffordability of anti-D immunoglobulin for many families.20PubMed Central. Prevalence of rhesus D-negative blood type and the challenges of rhesus D immunoprophylaxis among obstetric population in Ethiopia: a systematic review and meta-analysis Even within a single country, disparities can be stark. An analysis of the Mexican healthcare system found significant regional variations in anti-D immunoglobulin provision, with certain regions critically lacking access.21PubMed Central. Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management
Italy offers a more optimistic picture of what consistent policy can achieve, while still revealing imperfections. A national survey covering over 176,000 pregnancies found 136 cases of hemolytic disease due to anti-D antibodies, with 39 severe enough to require exchange transfusion.22PubMed Central. A survey of the current use of anti-D immunoprophylaxis and the incidence of haemolytic disease of the newborn in Italy The numbers are low relative to the population surveyed but not zero, reflecting the reality that no prevention program is 100% effective. Some women are sensitized before their first documented pregnancy, through earlier miscarriages, ectopic pregnancies, or blood transfusions. Others slip through the system because prophylaxis is given too late or not at all after a sensitizing event.
Nipocalimab and the Frontier of Antibody-Blocking Therapy
For the hardest cases, especially those involving mothers already heavily sensitized with antibodies against Kell or other antigens for which no prophylaxis exists, current treatment options are limited to serial intrauterine transfusions starting as early as the second trimester. A new therapeutic approach aims to stop the antibodies from reaching the fetus in the first place. Nipocalimab is a monoclonal antibody that blocks the neonatal Fc receptor, a molecular recycling system that normally keeps IgG antibodies circulating in the blood for weeks and ferries them across the placenta to the fetus.23PubMed. Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
By blocking this receptor, nipocalimab lowers the mother’s overall IgG levels and reduces the transfer of harmful antibodies to the fetus. In a phase 2 trial focused on early-onset severe hemolytic disease, maternal treatment with nipocalimab delayed or prevented fetal anemia compared to what would have been expected based on historical outcomes.24PubMed. Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn The approach raises an obvious question: if you lower the mother’s IgG across the board, not just the harmful antibodies, does the baby end up immunologically vulnerable after birth? Follow-up research from the same trial program has been investigating infant immunity after maternal nipocalimab treatment, an essential piece of the safety puzzle that will determine whether this drug moves toward wider use.
Nipocalimab is not a replacement for anti-D prophylaxis, which prevents the problem from starting. It is designed for the pregnancies where prevention has already failed and the mother carries dangerous levels of antibodies that current tools cannot neutralize. If the drug proves safe and effective in larger trials, it could fill a gap that intrauterine transfusion alone cannot cover, particularly in very early pregnancy before transfusion is technically feasible.
The RHD Gene Is More Complicated Than Positive or Negative
Most people think of Rh status as a simple binary: you are either Rh positive or Rh negative. In reality, the genetics are more complex. The RHD gene, which encodes the D antigen protein on red blood cells, comes in many variant forms. Some produce a weakened version of the D protein that may or may not be detected by standard blood typing, creating ambiguity about a person’s true Rh status. Among blood donors in one study from southeast Iran who initially typed as weak D, genetic analysis revealed a mix of partial D and weak D subtypes, each with different clinical implications for whether those individuals could be sensitized by D-positive blood or could sensitize a D-negative mother.25PubMed Central. RHD Genotyping of Rh-Negative and Weak D Phenotype among Blood Donors in Southeast Iran
Novel mutations in the RHD gene continue to be discovered. Chinese researchers recently identified two previously unknown variants in donors who typed as Rh negative. Both mutations disrupted splice sites in the gene, effectively shutting down production of the D protein despite the gene being present.26PubMed Central. Two novel variant allele of the RHD gene detected in two Chinese blood donors with the RHD negative phenotype These genetic subtleties matter for transfusion medicine and pregnancy management. A woman carrying a partial D variant might be classified as Rh positive in one lab and Rh negative in another, depending on the testing method. If she is treated as positive and does not receive anti-D prophylaxis, she could still become sensitized to the parts of the D protein she lacks. Molecular-level RHD genotyping is increasingly used to resolve these ambiguities, though it is not yet routine everywhere.